Novel approaches in the development of immunopotentiating reconstituted influenza virosomes as efficient antigen carrier systems

Vaccine

Volumn 21, Issue 7-8, 2003, Pages 611-615

  Gluck R ^a   Metcalfe, I C ^a  

^a Berna Biotech AG   (Switzerland)

Author keywords

Immunopotentiating reconstituted influenza virosomes (IRIVs); Novel; Vaccine

Indexed keywords

ANTIGEN; BACTERIAL VACCINE; DRUG CARRIER; GLYCOPROTEIN; INACTIVATED VIRUS VACCINE; POLYNUCLEOTIDE; RECOMBINANT PROTEIN; SYNTHETIC PEPTIDE; VIROSOME; VIROSOME VACCINE; VIRUS PROTEIN; VIRUS VACCINE;

CONFERENCE PAPER; DRUG DELIVERY SYSTEM; HUMAN; IMMUNOPOTENTIATION; INFLUENZA; PRIORITY JOURNAL; TARGET CELL; TUMOR CELL;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, VIRAL; HUMANS; IMMUNIZATION; INFLUENZA VACCINES; VACCINES, VIROSOME;

EID: 0037472438     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00567-4     Document Type: Conference Paper

References (21)

1. Glück R., Mischler R., Finkel B., Que J.U., Scarpa B., Cryz S.J. Jr. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet. 344(8916):1994;160-163.
2. Conne P., Gauthey L., Vernet P., Althaus B., Que J.U., Finkel B.et al. Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine. 15:1997;1675-1679.
3. Durrer P., Galli C., Hoenke S., Corti C., Glück R., Vorherr T.et al. H+-induced membrane insertion of influenza virus hemagglutinin involves the HA2 amino-terminal fusion peptide but not the coiled coil region. J. Biol. Chem. 271:1996;13417-13421.
4. Han X., Bushweller J.H., Cafiso D.S., Tamm L.K. Membrane structure and fusion-triggering conformational change of the fusion domain from influenza haemagglutinin. Nat. Struct. Biol. 8:2001;715-720.
5. Weber T., Paesold G., Galli C., Mischler R., Semenza G., Brunner J. Evidence for H(+)-induced insertion of influenza hemagglutinin HA2 N-terminal segment into viral membrane. J. Biol. Chem. 269:1994;18353-18358.
6. Epand R.F., Macosko J.C., Russell C.J., Shin Y.K., Epand R.M. The ectodomain of HA2 of influenza virus promotes rapid pH dependent membrane fusion. J. Mol. Biol. 286:1999;489-503.
7. Leikina E., LeDuc D.L., Macosko J.C., Epand Ra., Epand Ri., Shin Y.et al. The 1-127 HA2 construct of influenza virus hemagglutinin induces cell-cell hemifusion. Biochemistry. 40:2001;8378-8386.
8. Air G.M., Laver W.G. The neuraminidase of influenza virus. Proteins. 6:1989;341-356.
9. Bungener L., Serre K., Bijl L., Leserman L., Wilschut J., Daemen T.et al. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine. 20:2002;2287-2295.
10. Zurbriggen R., Novak-Hofer I., Seelig A., Glück R. IRIV-adjuvanted hepatitis A vaccine: in vivo absorption and biophysical characterisation. Prog. Lipid Res. 39:2000;3-18.
11. Hunziker I.P., Zurbriggen R., Glück R., Engler O.B., Reichen J., Dai W.J.et al. Perspectives: towards a peptide-based vaccine against hepatitis C virus. Mol. Immunol. 38:2001;475-484.
12. Cho J.E., Kim H.S., Ahn W.S., Park Y.S. Enhanced cytotoxicity of doxorubicin encapsulated in liposomes with reconstituted Sendai F-proteins. J. Microencapsulat. 18:2001;421-431.
13. Moreno R., Jiang L., Moehle K., Zurbriggen R., Glück R., Robinson J.A.et al. Exploiting conformationally constrained peptidomimetics and an efficient human-compatible delivery system in synthetic vaccine design. Chem. Biol. Chem. 2:2001;838-843.
14. Moreno R., Jiang L., Moehle K., Zurbriggen R., Glück R., Robinson J.A.et al. Exploiting conformationally constrained peptidomimetics and an efficient human compatible delivery system in synthetic vaccine design. Chem. Biol. Chem. 2:2001;838-844.
15. Pöltl-Frank F., Zurbriggen R., Helg A., Stuart F., Robinson J., Glück R.et al. Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide based vaccine. Clin. Exp. Immunol. 117:1999;496-503.
16. Zuckerman A.J., Zuckerman J.N. Prospects for a hepatitis C vaccine. J. Hepatol. 22:1995;97-100.
17. Hunziker I.P., Zurbriggen R., Glück R., Engler O.B., Reichen J., Dai W.J.et al. Perspectives: towards a peptide-based vaccine against hepatitis C virus. Mol. Immunol. 38:2001;475-484.
18. Glück U., Gebbers J.O., Glück R. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers. J. Virol. 73:1999;7780-7786.
19. Cusi M.G., Zurbriggen R., Valassina M., Bianchi S., Durrer P., Valensin P.E.et al. Intranasal immunisation with mumps virus DNA vaccine delivered by influenza virosomes elicits mucosal and systemic immunity. Virology. 277:2000;111-118.
20. Waelti E., Wegmann N., Schwaninger R.et al. Targeting HER-2/neu with antirat neu virosomes for cancer therapy. Cancer Res. 62:2002;437-444.
21. Holzer B.R., Hatz C., Schmidt-Sissolak D., Glück R., Althaus B., Egger M. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomised controlled trial. Vaccine. 14(10):1996;982-986.